HUTCHMED will host a webcast to discuss the data presented at the ASCO Annual Meeting at 8:30 -9:00 am HKT on Tuesday, June 3, 2025 (8:30 - 9:00 pm EDT on June 2, 2025). The event will be held in ...

Nxera and Lilly entered the multi-target collaboration in 2022 to leverage Nxera’s GPCR-focused structure-based drug design capabilities and Lilly’s extensive development, commercialization and ...

In the Phase 1/1b trial, ficerafusp alfa in combination with pembrolizumab resulted in deep and durable anti-tumor activity with improved overall survival (OS) compared to historical benchmarks in ...

Novartis is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety of Kisqali ® (ribociclib) plus endocrine therapy (ET, a non-steroidal ...